Sinco Pharmaceutical Holdings (HKSE:06833) Debt-to-Equity : 0.40 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Debt-to-Equity?

Sinco Pharmaceutical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$268 Mil. Sinco Pharmaceutical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$7 Mil. Sinco Pharmaceutical Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$687 Mil. Sinco Pharmaceutical Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sinco Pharmaceutical Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:06833' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.32 Med: 0.68 Max: 6.14
Current: 0.4

During the past 10 years, the highest Debt-to-Equity Ratio of Sinco Pharmaceutical Holdings was 6.14. The lowest was 0.32. And the median was 0.68.

HKSE:06833's Debt-to-Equity is ranked worse than
54.22% of 83 companies
in the Medical Distribution industry
Industry Median: 0.29 vs HKSE:06833: 0.40

Sinco Pharmaceutical Holdings Debt-to-Equity Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Debt-to-Equity Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

4.00

0.50

0.91

0.32

0.40

Sinco Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														0.91	0.57	0.32	0.35	0.40

Competitive Comparison of Sinco Pharmaceutical Holdings's Debt-to-Equity

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinco Pharmaceutical Holdings's Debt-to-Equity Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Debt-to-Equity falls into.

Sinco Pharmaceutical Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sinco Pharmaceutical Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(267.637	+	7.34)	/	686.95
	=	0.40

Sinco Pharmaceutical Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(267.637	+	7.34)	/	686.95
	=	0.40

Sinco Pharmaceutical Holdings (HKSE:06833) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sinco Pharmaceutical Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines